Developing a new HIV vaccine using specific T cells to boost immune response
Glycopeptide-specific helper T cells eliciting protective humoral immunity against HIV - Resubmission
This study is exploring a new HIV vaccine that aims to boost your immune system by training special cells to recognize and fight the virus, with the hope of providing better protection against HIV for everyone.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10800787 on NIH RePORTER |
What this research studies
This research focuses on creating a novel HIV vaccine that harnesses the body's immune system, specifically targeting helper T cells that recognize unique carbohydrate structures on the HIV virus. By activating these T cells, the goal is to stimulate the production of protective antibodies that can neutralize the virus. The approach involves understanding how these specialized T cells can enhance the immune response and lead to long-lasting protection against HIV. Patients may benefit from a more effective vaccine that could significantly reduce the risk of HIV infection.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk of HIV infection or those living with HIV who are seeking improved treatment options.
Not a fit: Patients who are already on effective antiretroviral therapy and have well-controlled HIV may not benefit directly from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking HIV vaccine that provides strong and lasting immunity against the virus.
How similar studies have performed: While there have been various approaches to HIV vaccine development, this specific strategy of targeting carbohydrate-specific T cells is innovative and has not been extensively tested in prior research.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Avci, Fikri Y — Emory University
- Study coordinator: Avci, Fikri Y
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.